Jeito Capital, a global private equity firm focused on biopharma, announced the final close of its second fund, Jeito II Fund, at $1.2 billion, exceeding its €1 billion target and marking the largest raise ever achieved by a fully independent European fund dedicated to biopharma.
With this milestone, Jeito Capital has tripled its assets under management to €1.6 billion in just five years, following the €534 million close of its first fund in 2021. The new fund reinforces the firm’s position among leading global biopharma investors and signals strong investor confidence in its patient-driven investment strategy.
Jeito II will continue the firm’s established approach of investing in 15 to 20 high-potential clinical-stage biopharma companies, primarily in Europe, that are developing breakthrough therapies targeting severe diseases and unmet medical needs. The fund also enables larger investments, with average commitments expected to reach up to €150 million per company, helping accelerate clinical development and commercialization.
The fund has already begun deploying capital across key therapeutic areas, including obesity, reproductive medicine, oncology, autoimmune and inflammatory diseases, neurology, and cardiometabolic conditions.
Jeito’s strategy is positioned against a backdrop of significant industry shifts, including a looming patent cliff that could reduce pharmaceutical revenues by as much as $400 billion by 2033. As large pharmaceutical companies increasingly rely on external innovation, with more than 70% of new drugs originating from smaller biopharma firms, Jeito aims to bridge funding gaps and scale emerging companies into global leaders.
The firm differentiates itself through a multidisciplinary team that supports portfolio companies across the full drug development lifecycle, from scientific research to regulatory strategy and commercialization. This approach has already contributed to notable exits, including acquisitions by major pharmaceutical companies valued at multi-billion dollars.
The Jeito II Fund attracted a broad and diversified base of global investors, including sovereign funds, pension funds, insurance companies, pharmaceutical corporations, and family offices across Europe, North America, and Asia.
Beyond its financial scale, the fund is also viewed as a strong signal for the European biopharma ecosystem, highlighting the region’s ability to support innovation with both capital and expertise. By addressing the shortage of long-term growth funding, Jeito aims to help European biopharma companies scale globally and compete at the highest level.
KEY QUOTES:
“The closing of Jeito II at more than one billion euros represents a very significant milestone for our business. This record fundraising is a collective success, reflecting the dedication and expertise of the entire Jeito team, the talent of its portfolio companies’ managers and the trust of our investors. We would like to thank them all for their hard work, dedication and support. It is also a strong signal for the European Biopharma ecosystem, demonstrating the growing conviction that European companies can drive major therapeutic innovation and significant economic benefits with the appropriate access to financial and strategic resources.”
Dr. Rafaèle Tordjman, Founder And CEO, Jeito Capital
“Jeito II continues a disciplined and proven strategy built around a clear conviction: some of the most compelling opportunities in Biopharma lie at the intersection of scientific excellence, strong unmet medical need and growing demand for differentiated innovation. In this environment, value creation requires both selectivity and continuity, backing the best companies, at the right time, with the right level of capital and expertise. Jeito is uniquely positioned to do so, thanks to a proven, differentiated methodology and to a team with the experience to provide both financing and significant industry expertise.”
Sabine Dandiguian, Managing Partner, Jeito Capital
